Cleveland Avenue, a venture capital investment company, led a $45m Series B funding round in Nuritas, a biotechnology company, with participation from Wheatsheaf Group, the European Circular Bioeconomy Fund, Vertex, Nutresa Ventures, CJ. Cultivian Sandbox Ventures and VisVires New Protein. “We are pleased to join Nuritas as it prepares to launch new consumer products alongside an impressive pipeline of novel molecules and ongoing partnerships with global consumer product businesses. Nuritas’ capabilities match Wheatsheaf’s mission to re-shape how food is produced and consumed while benefiting the environment and human health,” Stephan Dolezalek, Wheatsheaf Group Executive Director.